Ascendis Pharma A/S

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
13.60B
Market cap13.60B
Price-Earnings ratio
23.20
Price-Earnings ratio23.20
Dividend yield
Dividend yield
Average volume
577.15K
Average volume577.15K
High today
$224.11
High today$224.11
Low today
$216.50
Low today$216.50
Open price
$216.50
Open price$216.50
Volume
403.83K
Volume403.83K
52 Week high
$250.74
52 Week high$250.74
52 Week low
$160.86
52 Week low$160.86

Stock Snapshot

With a market cap of 13.6B, Ascendis Pharma A/S(ASND) trades at $218.06. The stock has a price-to-earnings ratio of 23.20.

On 2026-06-13, Ascendis Pharma A/S(ASND) stock traded between a low of $216.50 and a high of $224.11. Shares are currently priced at $218.06, which is +0.7% above the low and -2.7% below the high.

Ascendis Pharma A/S(ASND) shares are trading with a volume of 403.83K, against a daily average of 577.15K.

In the last year, Ascendis Pharma A/S(ASND) shares hit a 52-week high of $250.74 and a 52-week low of $160.86.

In the last year, Ascendis Pharma A/S(ASND) shares hit a 52-week high of $250.74 and a 52-week low of $160.86.

ASND News

Benzinga 1d
Why Is Ascendis Pharma Stock Gaining Friday? - Benzinga

...

Why Is Ascendis Pharma Stock Gaining Friday? - Benzinga
TipRanks 2d
Ascendis Pharma Reports Five-Year TransCon PTH Data Showing Sustained Benefits in Hypoparathyroidism

Ascendis Pharma ( (ASND) ) has shared an announcement. On June 11, 2026, Ascendis Pharma reported five-year data from its Phase 2 PaTH Forward trial showing th...

TipRanks 2d
Ascendis Pharma announces five-year data from PaTH Forward Trial

Ascendis Pharma (ASND) announced five-year data from its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH demonstrated sustained ef...

Analyst ratings

100%

of 19 ratings
Buy
100%
Hold
0%
Sell
0%

More ASND News

TipRanks 5d
Ascendis Pharma ‘oversold’ following ITC development, says Oppenheimer

Oppenheimer believes Ascendis Pharma (ASND) is oversold following a development in the ongoing ITC investigation into Yuviwel initiated by BioMarin (BMRN). Shou...

Simply Wall St 5d
Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Recent Share Price Weakness

Advertisement Recent share performance and business snapshot Ascendis Pharma (NasdaqGS:ASND) stock has been under pressure recently, with the share price down...

Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Recent Share Price Weakness

People also own

Based on the portfolios of people who own ASND. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.